Key result
LGMD2A is a slowly progressive disorder where null mutations lead to a more severe phenotype, while compound heterozygote patients are the least affected.
Observational (n=85)
Yes
This natural history study of LGMD2A delineates disease progression and phenotypic variability, providing essential data for determining endpoints in future clinical trials.
Answers are grounded in this paper and cite their sources.
Informs genotype-specific prognosis in LGMD2A; leaves open prospective validation for trial endpoints.
OBJECTIVE: Limb-girdle muscular dystophy 2A (LGMD2A, OMIM) is a slowly progressive myopathy caused by the deficiency in calpain 3, a calcium-dependent cysteine protease of the skeletal muscle. METHODS: In this study, we carried out an observational study of clinical manifestations and disease progression in genetically confirmed LGMD2A patients for up to 4 years. A total of 85 patients, aged 14-65 years, were recruited in three centers located in metropolitan France, the Basque country, and the Reunion Island. They were followed up every 6 months for 2 years and a subgroup was assessed annually thereafter for two more years. Data collected for all patients included clinical history, blood parameters, muscle strength assessed by manual muscle testing (MMT) and quantitative muscle testing, functional scores, and pulmonary and cardiac functions. In addition, CT scans of the lower limbs were performed in a subgroup of patients. RESULTS: Our study confirms the clinical description of a slowly progressive disorder with onset in the first or second decade of life with some degree of variability related to gender and mutation type. The null mutations lead to a more severe phenotype while compound heterozygote patients are the least affected. Muscle weakness is remarkably symmetrical and predominant in the axial muscles of the trunk and proximal muscles of the lower limb. There was a high correlation between the weakness at individual muscle level as assessed by MMT and the loss of density in CT scan analysis. INTERPRETATION: All the generated data will help to determine the endpoints for further clinical studies.
No takes yet. Share an insight, caveat, or question.
Hogrel et al. (2016) conducted an observational in Limb-girdle muscular dystrophy 2A (LGMD2A) (n=85). LGMD2A mutations was evaluated on Clinical manifestations and disease progression. LGMD2A is a slowly progressive disorder where null mutations lead to a more severe phenotype, while compound heterozygote patients are the least affected.
Synapse has enriched 10 related papers. Consider them for comparative context: